Alteration of glomerulogenesis- and podocyte structure-related gene expression in early diabetic nephropathy

References

• Grenfell A, Watkins PJ. Clinical diabetic nephropathy: natural history and complications. Clin. Endocrinol. Metab.15, 783–805 (1986).
   PubMedGoogle Scholar
• Adler AI, Stevens RJ, Manley SE et al. Development and progression of nephropathy in Type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int.63, 225–232 (2003).
   PubMed Web of Science ®Google Scholar
• Morgensen CE, Christensen CK, Vittinghus E. The stages in diabetic renal disease: with emphasis on the stage of incipint diabetic nephropahy. Diabetes32(Suppl. 2), 64–78 (1983).
   PubMed Web of Science ®Google Scholar
• Osterby R. Structual changes in diabetic kidney. Clin. Endocrinol. Metab.15, 733–751 (1986).
   PubMedGoogle Scholar
• Mauer SM, Steffes MW, Ellis EN, Sutherland DE, Brown DM, Goetz FC. Structual–functional relationship in diabetic nephropathy. J. Clin. Invest.74, 1143–1155 (1984).
   PubMed Web of Science ®Google Scholar
• Ellis EN, Steffes MW, Goetz FC, Sutherland DE. Glomerular filtration surface in Type 1 diabetes mellitus. Kidney Int.29, 889–894 (1986).
   PubMed Web of Science ®Google Scholar
• Olson JL, Laszik ZL. Diabetic nephropathy. In: Heptinstall’s Pathology of the Kidney (6th Edition). Lippincott Williams & Wilkins, PA, USA 803–852 (2007).
   Google Scholar
• Wolf G. New insights into the pathophisiology of diabetic nephropathy. Eur. J. Clin. Invest.34, 785–796 (2004).
   PubMed Web of Science ®Google Scholar
• Schrijvers BF, Flyvbjerg A, De Vriese A. The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int.65, 2003–2017 (2004).
   PubMed Web of Science ®Google Scholar
• Bonnet F, Cooper ME, Kawauchi H, Allen TJ, Boner G, Cao Z. Irbesartan normalizes the deficiency in glomerular nephrin expression in a model of diabetes and hypertension. Diabetologia44, 874–877 (2001).
   PubMed Web of Science ®Google Scholar
• Coimbra TM, Janssen U, Grone HJ et al. Early events leading to renal injury in obese Zucker (fatty) rats with Type II diabetes. Kidney Int.57, 167–182 (2000).
   PubMed Web of Science ®Google Scholar
• Wolf G, Chen S, Ziyadeh FN. From the periphery of the glomerular capillary wall toward the center disease. Podocyte injury comes of age in diabetic nephropathy. Diabetes54, 1626–1634 (2005).
   PubMed Web of Science ®Google Scholar
• Bjorn SF, Bangstad HJ, Hanssen KF. Glomerular epithelial foot processes and filtration slits in IDDM diabetic patients. Diabetologia38, 1197–1204 (1995).
   PubMed Web of Science ®Google Scholar
• Vernier RL, Steffes MW, Sisson-Ross S, Mauer SM. Heparan sulfate proteoglycan in the glomerular basement membrane in Type 1 diabetes mellitus. Kidney Int.41, 1070–1080 (1992).
   PubMed Web of Science ®Google Scholar
• Liu Y. Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic intervention. J. Am. Soc. Nephrol.15, 1–12 (2004).
   PubMed Web of Science ®Google Scholar
• Makino H, Miyamoto Y, Sawai K et al. Altered gene expression related to glomerulogenesis and podocyte structure in early diabetic nephropathy of db/db mice and its restoration by pioglitazone. Diabetes55, 2747–2756 (2006).
   PubMed Web of Science ®Google Scholar
• Clark AT, Young RJ, Bertram JF. In vitro studies on the roles of transforming growth factor-β1 in rat metanephric development Kidney Int.59, 1641–1653 (2001).
   PubMed Web of Science ®Google Scholar
• Lui A, Dardik A, Ballermann BJ. Neutralizing TGF-β1 antibody infusion in neonatal rat delays in vivo glomerullar capillary formation. Kidney Int.56, 1334–1348 (1999).
   PubMed Web of Science ®Google Scholar
• Makino H, Mukoyama M, Sugawara A et al. Expression of connective tissue growth factor in early streptozotocin-induced diabetic rat kidney: effect of aspirin treatment. Clin. Exp. Nephrol.7, 33–40 (2003).
   PubMedGoogle Scholar
• Wahab NA, Schaefer L, Weston BS et al. Glomerular expression of thrombospondin-1, transforming growth factor β and connective tissue growth factor at different stages of diabetic nephropathy and their interdependent roles in mesangial response to diabetic stimuli. Diabetologia48, 2650–2660 (2005).
   PubMed Web of Science ®Google Scholar
• Sharma K, Ziyadeh FN. Biochemical events and cytokine interactions linking glucose metabolism to the development of diabetic nephropathy. Semin. Nephrol.17, 80–92 (1997).
   PubMed Web of Science ®Google Scholar
• Han SY, Jee YH, Han KH et al. An imbalance between matrix metalloproteinase-2 and tissue inhibitor of matrix metalloprotease-2 contributes to the development of early diabetic nephropathy. Nephrol. Dial. Transplant.21, 2406–2416 (2006).
   PubMed Web of Science ®Google Scholar
• Monkawa T, Hiromura K, Wolf G, Shankland SJ. The hypertrophic effect of transforming growth factor-β is reduced in the absence of cycline-dependent kinase-inhibitors p21 and p27. J. Am. Soc. Nephrol.13, 1172–1178 (2002).
   PubMed Web of Science ®Google Scholar
• Ziyadeh FN, Hoffman BB, Han DC et al. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-β antibody in db/db diabetic mice. Proc. Natl Acad. Sci. USA97, 8015–8020 (2000).
   PubMed Web of Science ®Google Scholar
• Ding G, Reddy K, Kapasi AA et al. Angiotensin II induces apoptosis in rat glomerular epithelial cells. Am. J. Physiol. Renal Physiol.238, F173–F180 (2002).
   Google Scholar
• Iglesias-de la Cruz MC, Ziyadeh FN, Isono M et al. Effects of high glucose and TGF-β1 on the expression of collagen IV and vascular endothelial growth factor in mouse podocytes. Kidney Int.62, 901–913 (2002).
   PubMed Web of Science ®Google Scholar
• Dudley AT, Lyons KM, Robertson EJ. A requirement for bone morphogenetic protein-7 during development of the mammalian kidney and eye. Genes Dev.9, 2795–2807 (1995).
   PubMed Web of Science ®Google Scholar
• Wang S, Hirschberg R. Bone morphogenetic protein-7 signals opposing transforming growth factor β in mesangial cells. J. Biol. Chem.279, 23200–23206 (2004).
   PubMed Web of Science ®Google Scholar
• Wang S, de Caestecker M, Kopp J, Mitu G, Lapage J, Hirschberg R. Renal bone morphogenetic protein-7 protects against diabetic nephropathy. J. Am. Soc. Nephrol.17, 2504–2512 (2006).
   PubMed Web of Science ®Google Scholar
• Wang SN, Lapage J, Hirschberg R. Loss of tubular bone morphogenic protein-7 in diabetic nephropathy. J. Am. Soc. Nephrol.12, 2392–2399 (2001).
   PubMed Web of Science ®Google Scholar
• Topol LZ, Bardot B, Zhang Q et al. Biosynthesis, post-translation modification, and functional characterization of Drm/Gremlin. J. Biol. Chem.275, 8785–8793 (2000).
   PubMed Web of Science ®Google Scholar
• Hsu DR, Economides AN, Wang X, Eimon PM, Harland RM. The Xenopus dorsalizing factor gremlin identifies a novel family of secreted proteins that antagonize BMP activities. Mol. Cell1, 673–683 (1998).
   PubMed Web of Science ®Google Scholar
• Michos O, Panman L, Vintersten K, Beier K, Zeller R, Zuniga A. Gremlin-mediated BMP antagonism induces the epithelial–mesenchymal feedback signaling controlling metanephric kidney and limb organogenesis. Development131, 3401–3410 (2004).
   PubMed Web of Science ®Google Scholar
• McMahon RA, Murphy M, Clarkson M et al. IHG-2, a mesangial cell gene induced by high glucose, is human gremlin. J. Biol. Chem.275, 9901–9904 (2000).
   PubMed Web of Science ®Google Scholar
• Dolan V, Murphy M, Sadlier D et al. Expression of gremlin, a bone morphogenetic protein antagonist, in human diabetic nephropathy. Am. J. Kidney Dis.45, 1034–1039 (2005).
   PubMed Web of Science ®Google Scholar
• Murphy M, McMahon RA, Clarkson M et al. Induction of gremlin expression in the remnant kidney in vivo and during TGF-induced epithelial mesenchymal transformation in vitro. J. Am. Soc. Nephrol.11, 625A (2000).
   PubMed Web of Science ®Google Scholar
• Ichinose K, Maeshima Y, Yamamoto Y et al. 2-(8-hydroxy-6-methoxy-oxo-1H-2-benzopyran-3yl) propionic, an inhibitor of angiogenesis, ameriorates renal alteration in obese Type 2 diabetic mice. Diabetes55, 1232–1242 (2006).
   PubMed Web of Science ®Google Scholar
• Nyengaad JR, Rasch R. The impact of experimental diabetes mellitus in rats on glomerular capillary number and sizes. Diabetologia36, 189–194 (1993).
   PubMed Web of Science ®Google Scholar
• Kitamoto Y, Tokunaga H, Miyamoto K, Tomita K. VEGF is an essential molecule for glomerular structuring. Nephrol. Dial. Transplant.17, S25–S27 (2002).
   PubMed Web of Science ®Google Scholar
• Kitamoto Y, Tokunaga H, Tomita K. Vascular endothelial growth factor is an essential molecule for mouse kidney development: glomerulogenesis and nephrogenesis. J. Clin. Invest.99, 2351–2357 (1997).
   PubMed Web of Science ®Google Scholar
• Gerber HP, Hillan KJ, Ryan AM et al. VEGF is required for growth and survival in neonatal mice. Development126, 1149–1159 (1999).
   PubMed Web of Science ®Google Scholar
• Bailey E, Bottomley MJ, Westwell S et al. Vascular endothelial growth factor mRNA expression in minimal change, membranous, and diabetic nephropathy demonstrated by non-isotropic in situ hybridization. J. Clin. Pathol.52, 735–738 (1999).
   PubMed Web of Science ®Google Scholar
• Rizkalla B, Forbes JM, Cooper ME, Cao Z. Increased renal vascular endothelial growth factor and angiopoietins by angiotensin II infusion is mediated by both AT1 and AT2 receptors. J. Am. Soc. Nephrol.14, 3061–3071 (2003).
   PubMed Web of Science ®Google Scholar
• Hoshi S, Nomoto K, Kuromitsu J, Tomari S, Nagata M. High glucose induced VEGF expression via PKC and ERK in glomerular podocytes. Biochem. Biophys. Res. Commun.290, 177–184 (2002).
   PubMed Web of Science ®Google Scholar
• Flyvbjerg A, Dagnes-Hansen F, De Vriese AS et al. Amelioration of long-term renal changes in obese Type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody. Diabetes51, 3090–3094 (2002).
   PubMed Web of Science ®Google Scholar
• Chen S, Kasama Y, Lee JS, Jim B, Marin M, Ziyadeh FN. Podocyte-derived vascular endothelial growth factor mediates the stimulation of α2(IV) collagen production by transforming growth factor-β 1 in mouse podocytes. Diabetes53, 2939–2949 (2004).
   PubMed Web of Science ®Google Scholar
• Sung SH, Ziyadeh FN, Wang A, Pyagay PE, Kanwar YS, Chen S. Blockade of vascular endothelial growth factor signaling ameliorates diabetic albuminuria in mice. J. Am. Soc. Nephrol.17, 3093–3104 (2006).
   PubMed Web of Science ®Google Scholar
• Woolf AS, Yuan HT. Angiopoietin growth factors and Tie receptor tyrosine kinases in renal vascular development. Pediatr. Nephrol.16, 177–184 (2001).
   PubMed Web of Science ®Google Scholar
• Suri C, Jones PF, Palan S et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell87, 1171–1180 (1996).
   PubMed Web of Science ®Google Scholar
• Maisonpierre PC, Suri C, Jones PF et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science277, 55–60 (1997).
   PubMed Web of Science ®Google Scholar
• Freeburg PB, Robert B, St John PL, Abrahamson DR. Podocyte expression of hypoxia-inducible factor (HIF)-1 and HIF-2 during glomerular development. J. Am. Soc. Nephrol.14, 927–938 (2003).
   PubMed Web of Science ®Google Scholar
• Doronzo G, Russo I, Mattiello L Riganti C, Anfossi G, Trovati M. Insulin activates hypoxia-inducible factor-1α in human and rat vascular smooth muscle cells via phosphatidylinositol-3 kinase and mitogen-activated protein kinase pathways: impairment in insulin resistance owing to defects in insulin signalling. Diabetologia49, 1049–1063 (2006).
   PubMed Web of Science ®Google Scholar
• Treins C, Giorgetti-Peraldi S, Murdaca J, Van Obberghen E. Regulation of vascular endothelial growth factor expression by advanced glycation end products. J. Biol. Chem.276, 43836–43841 (2001).
   PubMed Web of Science ®Google Scholar
• Haase VH. Hypoxia-inducible factors in the kidney. Am. J. Physiol. Renal Physiol.291, F271–F281 (2006).
   PubMedGoogle Scholar
• Takahashi T, Takahashi K, Gerety S, Wang H, Anderson DJ, Daniel TO. Temporally compartmentalized expression of ephrin B2 during renal glomerular development. J. Am. Soc. Nephrol.12, 2673–2682 (2001).
   PubMed Web of Science ®Google Scholar
• Foo SS, Tumer CJ, Adams S et al. Ephrin-B2 controls cell motility and adhesion during blood-vessel-wall assembly. Cell124, 161–173 (2006).
   PubMed Web of Science ®Google Scholar
• Iglesias P, Diez JJ. Peroxisome proliferator-activated receptor γ agonists in renal disease. Eur. J. Endocrinol.154, 613–621 (2006).
   PubMed Web of Science ®Google Scholar
• Wharram BL, Goyal M, Gillespie PJ et al. Altered podocyte structure is GLEPP1 (Ptpro)-deficient mice associated with hypertension and low glomerular filtration rate. J. Clin. Invest.106, 1281–1290 (2000).
   PubMed Web of Science ®Google Scholar
• Kim YH, Goyal M, Wharram B, Wiggins J, Kershaw D, Wiggins R. GLEPP1 receptor tyrosine phosphatase (Ptpro) in rat PAN nephrosis. Nephron90, 471–476 (2002).
   PubMed Web of Science ®Google Scholar
• Quaggin SE, Van den Heuvel GB, Igarashi P. Pod-1, a mesoderm-specific basic-helix–loop–helix protein expressed in mesenchymal and glomerular epithelial cells in the developing kidney. Mech. Dev.71, 37–48 (1998).
   PubMed Web of Science ®Google Scholar
• Mundel P, Shankland SJ. Podocyte biology and response to injury. J. Am. Soc. Nephrol.13, 3005 (2002).
   PubMed Web of Science ®Google Scholar
• Tryggvason K, Patrakka J, Wartiovaara J. Hereditary proteinuria syndromes and mechanisms of proteinuria. N. Engl. J. Med.354, 1387–1401 (2006).
   PubMed Web of Science ®Google Scholar
• Kelly DJ, Aaltonen P, Cox AJ et al. Expression of slit diaphragm protein, nephrin, in experimental diabetic nephropathy: differing effect of anti-proteinuric therapies. Nephrol. Dial. Transplant.17, 1327–1332 (2002).
   PubMed Web of Science ®Google Scholar
• Doublier S, Salvidio G, Lupia E et al. Nephrin expression is reduced in human diabetic nephropathy. Evidence for distinct role for glycated albumin and angiotensin II. Diabetes52, 1023–1030 (2003).
   PubMed Web of Science ®Google Scholar
• Pätäri A, Forsblom C, Havana M, Taipale H, Groop PH, Holthöfer H. Nephrinemia in diabetic nephropathy of Type 1 diabetes. Diabetes52, 2969–2974 (2003).
   PubMed Web of Science ®Google Scholar
• Nosadini R, Velussi M, Brocco E et al. Altered transcapillary escape of albumin and microalbuminuria reflects two different pathogenetic mechanisms. Diabetes54, 228–233 (2005).
   PubMed Web of Science ®Google Scholar
• Gonzales-Mariscal L, Betanzos A, Avila-Flores A. MAGUK proteins: structure and role in the tight junction. Semin. Cell Dev. Biol.11, 315–324 (2000).
   PubMed Web of Science ®Google Scholar
• Choles HR, Vasylyeva TL, Pergola PE et al. ZO-1 expression and phosphorylation in diabetic nephropathy. Diabetes55, 894–900 (2006).
   PubMed Web of Science ®Google Scholar
• Kaplan JM, Kim SH, North KN et al. Mutations in ACTN4, encoding α-actinin-4, cause familial focal segmental glomerulosclerosis. Nat. Genet.24, 251–256 (2000).
   PubMed Web of Science ®Google Scholar
• Michaud JL, Lemieux LI, Dube M, Vanderhyden BC, Robertson SJ, Kennedy CR. Focal and segmental glomerulosclerosis in mice with podocyte-specific expression of mutant α-actinin-4. J. Am. Soc. Nephrol.14, 1200–1211 (2003).
   PubMed Web of Science ®Google Scholar
• Ha TS. High glucose and advanced glycosylated end-products affect the expression of α-actinin-4 in glomerular epithelial cells. Nephrology11, 435–441 (2006).
   PubMed Web of Science ®Google Scholar
• Kojima K, Kerjaschki D. Is podocyte shape controlled by the dystroglycan complex. Nephrol. Dial. Transplant.17, S23–S24 (2002).
   PubMed Web of Science ®Google Scholar